Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
945 articles
The therapeutic landscape for ATTR-CM is evolving rapidly, with new targeted agents challenging how clinicians choose and sequence treatment.
A prospective trial shows sotatercept reduces right ventricular afterload and remodels heart mechanics, improving functional reserve in pulmonary arterial hypertension.
A phase 2 trial shows lumacaftor, repurposed from cystic fibrosis, safely corrects a lethal arrhythmia syndrome via precision protein-trafficking repair.
A landmark Lancet Series reveals PAD's catastrophic 5-year mortality rivals severe cancer, yet it remains massively underdiagnosed and undertreated.
A new review in the European Heart Journal argues that autoimmune mechanisms are an underappreciated cause of unexpected cardiac arrest in young, seemingly healthy people.
A 480,000-person study finds high inflammation raises heart attack and stroke risk by 43%, with structural heart changes beginning silently years earlier.
A European Heart Journal review unpacks the links between atrial fibrillation and sudden cardiac death, spotlighting novel therapeutic targets.
A secondary analysis of a global randomized trial compares three dual single-pill combinations for blood pressure control, with direct implications for cardiovascular aging.
A meta-analysis of 13 RCTs finds exercise-based telerehab significantly improves cardiorespiratory fitness in CVD patients, but fails to reduce blood pressure.
Isometric wall sits trigger a nitric oxide surge that relaxes arteries and lowers blood pressure — with only 24 minutes of effort per week.
A landmark review reveals that simultaneous exposure to noise, air pollution, and chemicals creates synergistic cardiovascular harm that single-pollutant studies drastically underestimate.
A 2-year RCT finds that reducing plasma erythritol through dietary intervention cuts cardiovascular risk scores and improves dangerous lipid subtypes.
